Eledon Pharmaceuticals Company Profile - aVenture Research
Eledon Pharmaceuticals
Eledon Pharmaceuticals, a clinical-stage biotech company, develops an anti-CD40L antibody for people with type 1 diabetes and difficult-to-control blood sugars.
Eledon Pharmaceuticals is a clinical-stage biotechnology company targeting the CD40 Ligand pathway and developing therapies to protect transplanted organs and prevent rejection. Otic completed a reverse merger with Tokai Pharmaceuticals, which then changed its name to Novus Therapeutics. Novus Therapeutics was later renamed Eledon Pharmaceuticals.
Tegoprubart, Eledon’s lead compound, is an anti-CD40L antibody that regulates the drivers of immune attack on a transplanted organ. Current immunosuppressive therapies can cause kidney damage, diabetes, high blood pressure, headaches, and tremors, and transplant immunosuppression and outcomes have changed very little in over 30 years. Islet cell transplantation for type 1 diabetes depends on calcineurin inhibitors that can damage the cells they protect; Eledon targets people with type 1 diabetes and severe, difficult-to-control blood sugars.